Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group
| Autor: | Reck, M., Von Pawel, J., Fischer, J. R., Kortsik, C., Bohnet, S., von Eiff, M., Koester, W., Thomas, M., Schnabel, P., Deppermann, K. M., German Thoracic Oncology Working Group |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.drug_class Medizin Phases of clinical research Tyrosine-kinase inhibitor Thoracic Oncology Internal medicine medicine Carcinoma Epidermal growth factor receptor Lung integumentary system biology business.industry medicine.disease respiratory tract diseases Surgery medicine.anatomical_structure biology.protein Erlotinib Non small cell business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:7565-7565 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.7565 |
| Popis: | 7565 Background: Treatment of elderly patients remains a challenge. We compared the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib which has shown promising resul... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|